Clinical Professionals’ Acquisition by CPL

Yvette Cleland CEO of Clinical Professionals Ltd is delighted to announce its acquisition by Ireland’s leading employment services group, CPL Resources PLC. As Europe’s leading life science staffing company we strive to provide the highest quality service for both candidates and clients whilst priding ourselves in being innovators within the life science industry. The acquisition

Continue Reading

Clinigen Announce Acquisition of Idis for £225m

The Clinigen Group have announced that they are acquiring Idis for £225 million. The acquisition with Idis, an unlicensed medicines supplier, will make the Clinigen Group the global leader in unlicensed medicines.  The ethical unlicensed supply market is estimated to be worth in excess of $5bn. Idis supplies unlicensed medicines predominantly on an exclusive basis

Continue Reading

European Regulatory Approval for Eli Lilly / Boehringer’s Abasria

The European Commission has granted regulatory approval to Eli Lilly and Boehringer Ingelheim’s Abasria for treating diabetes in adults, adolescents and children aged two years and above. The approval follows EMA’s Committee for Medicinal Products for Human Use (CHMP) positive recommendation earlier this year. The previous recommendation noted that clinical studies of the insulin showed

Continue Reading

European Regulatory Body Approves Sanofi Pasteur MSD’s Gardasil

European regulators have approved Sanofi Pasteur MSD’s cervical cancer vaccine, Gardasil, for the prevention of anal cancer. The European Commission granted marketing authorisation to Gardasil to be used in the prevention of anal precancerous lesions and anal cancers causally related to certain oncogenic human papillomavirus types in both males and females. Roughly 6,800 patients are

Continue Reading

NICE Halts Second-Line Use of Tarceva

NHS cost regulatory body, NICE, have today published updated draft guidance, proposing to stop backing the second-line use of Tarceva (erlotinib) to treat relapsed non-small cell lung cancer (NSCLC). Following a review of the existing guidance the National Institute for Health and Care Excellence (NICE) has decided that treatment after first-line therapy has failed is

Continue Reading

Merck Announce Cut of 8,500 Jobs

Merck & Co have unveiled plans to cut around 8,500 jobs, in addition to previously-announced cuts of 7,500 roles, in an attempt to decrease costs and improve competitiveness. Merck are expecting to make $2.50 billion in yearly cost savings by the end of 2015 and the majority of this will come from a reduction of

Continue Reading